2024 Tandem Meetings: Focus on GVHD
The 2024 Tandem Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, held February 21-24, 2024, featured presentations by international experts and provided attendees with updates on critical research, new technologies, and innovation in hematopoietic stem cell transplantation and cellular therapy. Find highlights from the sessions that are most relevant to oncology nurses, including those with a focus on graft-versus-host-disease (GVHD).
Mary Mansour Riwes, DO, explains what she saw as the important news in GVHD at the 2024 Tandem Meetings.
Mary Mansour Riwes, DO, speaks about research on the topic that she presented at the 2024 Tandem Meetings.
High-dose PTCy is the “standard of care" for certain patients but the “optimal dosing of PTCy has not been defined."
The 3-year follow-up analysis included 152 patients with cGVHD who received 2-5 prior lines of systemic therapy.
GVHD Clinician, Researcher Shares Highlights From 2024 Tandem Transplant & Cellular Therapy Meetings
Stephanie J. Lee, MD, MPH, speaks about what she sees as the key GVHD highlights at the Tandem Meetings.
Contrast-enhanced ultrasonography is a noninvasive method that "could contribute to GVHD diagnosis and management guidance."
The study showed a certain type of aGVHD is the predominant form that occurs after PTCy-based prophylaxis.
The randomized, double-blind trial evaluated the efficacy and safety of ruxolitinib 1.5% cream.
The current diagnostic criteria for CNS GVHD “does not cover a majority of cases with strong clinical suspicion."
Dr. Lee speaks about study evaluating belumosudil in cGVHD and highlights the critical role of nurses in GVHD care.
The phase III BMT CTN 1301 trial evaluated CNI-free strategies using T-cell depletion without additional immune suppression.
A team implemented a database that obtained “near real-time” information on GVHD-related telehealth visits.
The combination was “exceptionally potent in diminishing” aGVHD, but there was 1 risk factor for developing aGVHD.
The off-the-shelf allogeneic CAR-T product is under development for the treatment of relapsed or refractory T-cell ALL/LBL.
Orca-T uses "highly purified, polyclonal donor regulatory T cells to control alloreactive immune responses."
Researchers aimed to clarify “varying results” from previous research on the relationship between obesity and HSCT ...
The first report of dual of belumosudil-ruxolitinib therapy for advanced cGVHD "demonstrated a robust treatment response."
New research shows why a child's age at the time of allogeneic transplant is a critical consideration.
Erin Winters, RN, BSN, BMTCN, chair of the ASTCT Nursing SIG, discusses highlights from the 2024 Tandem Meetings.
A new study provides unique insights on the outcomes of patients who developed GVHD after the CAST regimen.
Belumosudil was associated with “high treatment response and survival outcomes” in patients with advanced cGVHD.
Learn how a team implemented nurse navigator transition visits and survivorship care plans for survivors of HSCT.
It was important to provide the virtual clinic for GVHD because "focused clinics providing such care is limited."
Advertisement
Advertisement
